Works matching IS 17762596 AND DT 2023 AND VI 18 AND IP 1


Results: 9
    1
    2
    3

    Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 1, p. 139, doi. 10.1007/s11523-022-00933-7
    By:
    • Rimini, Margherita;
    • Fabregat-Franco, Carles;
    • Persano, Mara;
    • Burgio, Valentina;
    • Bergamo, Francesca;
    • Niger, Monica;
    • Scartozzi, Mario;
    • Rapposelli, Ilario Giovanni;
    • Aprile, Giuseppe;
    • Ratti, Francesca;
    • Pedica, Federica;
    • Verdaguer, Helena;
    • Rizzato, Mario;
    • Nichetti, Federico;
    • Lai, Eleonora;
    • Cappetta, Alessandro;
    • Macarulla, Teresa;
    • Fassan, Matteo;
    • De Braud, Filippo;
    • Pretta, Andrea
    Publication type:
    Article
    4
    5

    Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 1, p. 105, doi. 10.1007/s11523-022-00931-9
    By:
    • Kollmannsberger, Christian;
    • Hurwitz, Herbert;
    • Bazhenova, Lyudmila;
    • Cho, Byoung Chul;
    • Hong, David;
    • Park, Keunchil;
    • Reckamp, Karen L.;
    • Sharma, Sunil;
    • Der-Torossian, Hirak;
    • Christensen, James G.;
    • Faltaos, Demiana;
    • Potvin, Diane;
    • Tassell, Vanessa;
    • Chao, Richard;
    • Shapiro, Geoffrey I.
    Publication type:
    Article
    6
    7
    8
    9